Generic Name and Formulations:
Nitroglycerin 0.1mg/hr, 0.2mg/hr, 0.4mg/hr, 0.6mg/hr; transdermal patches.
Valeant Pharmaceuticals, Inc
Indications for MINITRAN:
Prophylaxis of angina. Not for acute attacks.
Initially one 0.2mg/hr or 0.4mg/hr patch for 12–14hrs/day. Remove patch for 10–12hrs/day.
Acute or recent MI. Volume depletion. Hypotension. Heart failure. Hypertrophic cardiomyopathy. Reduce dose or discontinue if hypotension occurs. Remove before defibrillation or cardioversion. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, dizziness, flushing, hypotension, increased angina, tachycardia, faintness, nausea, vomiting, rash.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Predictors of Opioid Overdose in High-Risk Users
- FDA to Review Long-Acting Treatment for Opioid Use Disorder
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment
- The Fight for Patient Privacy Under Big Data Analytics